Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Actinogen Medical ( (AU:ACW) ).
Actinogen Medical Limited has applied for quotation on the ASX of 113,617,184 new ordinary fully paid shares, expanding its listed securities under the code ACW. The issuance, dated 2 March 2026, forms part of previously announced transactions and will increase the company’s free float and capital base, potentially enhancing liquidity for investors and supporting future corporate and development initiatives.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited is an ASX-listed biotechnology company focused on developing medical therapies, with its ordinary fully paid shares traded under the ticker ACW. The company operates in the life sciences sector and raises capital through equity issuance to support its research, development, and operational activities.
YTD Price Performance: -32.79%
Average Trading Volume: 5,234,306
Technical Sentiment Signal: Sell
Current Market Cap: A$141.9M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.